Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease – results of the IMAPA study

Ferguson, L. et al. (2021) Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease – results of the IMAPA study. Rheumatology, (doi: 10.1093/rheumatology/keab474) (PMID:34097014) (Early Online Publication)

[img] Text
243691.pdf - Published Version
Available under License Creative Commons Attribution.



Objectives: Studies have suggested phosphodiesterase 4 (PDE4) inhibition may be associated with weight loss and other cardiometabolic benefits. We evaluated the effect of the PDE4 inhibitor apremilast on body weight and composition, glucose homeostasis, lipid profiles, and vascular function in psoriatic disease, and whether weight change correlated with therapeutic response. Methods: We conducted a prospective, open label study (Immune Metabolic Associations in Psoriatic Arthritis, IMAPA) of adults receiving apremilast 30 mg as part of routine care for psoriatic arthritis and/or psoriasis. Cardiometabolic, anthropometric, and disease activity assessments were performed at baseline (pre-apremilast) and at months 1, 3, and 6 of apremilast treatment in 60 patients. A subgroup underwent further assessment of endothelial function, body composition, and adipocyte morphology. Results: In patients (median age 54.5 years, 63% women, median BMI 33.2 kg/m2) apremilast was associated with a mean weight loss of 2.2 kg (95% CI 1.4–3.0 kg, p< 0.001) and mean BMI decrease of 0.8 kg/m2 (95% CI 0.5–1.2 kg/m2, p< 0.001) after 6 months treatment. Body composition analysis demonstrated a reduction in total abdominal fat (mean decrease 0.52 L, 95% CI 0.08–0.96L, p= 0.022), principally subcutaneous adipose tissue (mean decrease 0.37 L, 95% CI 0.05–0.68L, p= 0.022). There was no change in adipocyte diameter, HbA1c, lipid, GLP-1, or vascular function. Psoriatic disease activity improved with apremilast, although this was not correlated with weight change. Conclusion: Following apremilast treatment, we observed weight loss, principally abdominal subcutaneous fat, and improvement in psoriatic disease activity. The latter was independent of weight change, suggesting apremilast likely acts through direct immunological mechanisms.

Item Type:Articles
Status:Early Online Publication
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Brooksbank, Dr Katriona and Ferguson, Dr Lyn and Welsh, Dr Paul and Siebert, Professor Stefan and Sattar, Professor Naveed and Radjenovic, Dr Aleksandra and Paterson, Miss Caron
Authors: Ferguson, L., Cathcart, S., Rimmer, D., Semple, G., Brooksbank, K., Paterson, C., Brown, R., Harvie, J., Gao, X., Radjenovic, A., Welsh, P., McInnes, I. B., Sattar, N., and Siebert, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Rheumatology
Publisher:Oxford University Press
ISSN (Online):1462-0332
Published Online:07 June 2021
Copyright Holders:Copyright © The Author(s) 2021
First Published:First published in Rheumatology 2021
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
190814BHF centre of excellenceRhian TouyzBritish Heart Foundation (BHF)RE/13/5/30177Institute of Cardiovascular & Medical Sciences